IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

BACKGROUND: (blind field). METHODS: RNA expression profiling was performed using DASL (Illumina) on 185 samples of which 113 were derived from BELOB trial samples and 72 were used to test the performance of the platform. RNA sequencing was performed on 96 samples, 78 of which were from BELOB trial s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: French, Pim, Erdem-Eraslan, L., Kros, J.M., Oosterkamp, H.M., Walenkamp, A.M.E., Beerepoot, L., Hanse, M., Buter, J., Honkoop, A., van der Holt, B., Vernhout, R.M., Sillevis Smitt, P.A.E., Taal, W., van den Bent, M.J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144494/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou206.29
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares